Shanghai issues a new set of policies and financial incentives designed to support and speed up regulatory and commercial activities in the biopharma sector, in a comprehensive stimulus package for companies based in the major Chinese city.

RNK Pharma founder and CEO Yaning Wang joins Brian Yang to discuss the latest biopharma stimulus policies offered by Shanghai and the globalization of China biotech. Dexter Yan also talks about China biotech initial public offering trends in the first half of this year. 

Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.

The global battle of the blockbuster obesity drugs appears set to come to China with the approval of Lilly's Mounjaro, although domestic competitors are fast catching up. 

The anticipated business rebound for China after its post-COVID reopening of markets in 2023 has not materialized and structural market issues continue to affect EU firms' China sentiment.

A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.